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Abstract
Background: Immunotherapy has shown remarkable clinical promise in the treatment of various types of cancers.
However, clinical benefits derive from a highly inflammatory mechanism of action. This presents unique challenges for
use in pediatric brainstem tumors including diffuse intrinsic pontine glioma (DIPG), since treatment-related inflammation
could cause catastrophic toxicity. Therefore, the goal of this study was to investigate whether inflammatory, immune-
based therapies are likely to be too dangerous to pursue for the treatment of pediatric brainstem tumors.
Methods: To complement previous immunotherapy studies using patient-derived xenografts in immunodeficient mice,
we developed fully immunocompetent models of immunotherapy using transplantable, syngeneic tumors. These four
models – HSVtk/GCV suicide gene immunotherapy, oncolytic viroimmunotherapy, adoptive T cell transfer, and CAR T cell
therapy – have been optimized to treat tumors outside of the CNS and induce a broad spectrum of inflammatory
profiles, maximizing the chances of observing brainstem toxicity.
Results: All four models achieved anti-tumor efficacy in the absence of toxicity, with the exception of recombinant
vaccinia virus expressing GMCSF, which demonstrated inflammatory toxicity. Histology, imaging, and flow cytometry
confirmed the presence of brainstem inflammation in all models. Where used, the addition of immune checkpoint
blockade did not introduce toxicity.
Conclusions: It remains imperative to regard the brainstem with caution for immunotherapeutic intervention.
Nonetheless, we show that further careful development of immunotherapies for pediatric brainstem tumors is warranted
to harness the potential potency of anti-tumor immune responses, despite their possible toxicity within this anatomically
sensitive location.
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Background
Brain tumors are the leading cause of pediatric cancer
death [1]. Ten to 15 % of these tumors occur in the
brainstem, most of which are a uniformly fatal disease
classified as an H3K27M-mutant diffuse midline glioma,
or historically, diffuse intrinsic pontine glioma (DIPG)
[2, 3]. Radiation extends survival by several months and
dexamethasone is used for symptomatic control, but
unfortunately, decades of clinical research have not in-
creased median overall survival beyond 9–11months [2].
Cancer immunotherapy is among the most promising
areas of biomedical research, with recent FDA approval
of the first chimeric antigen receptor (CAR) T cell [4]
and oncolytic virus [5] therapies. In addition to strong
anti-tumor activity, these treatments have the potential
to provide long-term cancer immunosurveillance
through the generation of immunologic memory [6, 7].
Furthermore, while traditional chemotherapy and radi-
ation have long-term, developmental effects on pediatric
patients [8], clinical studies in adults suggest that im-
munotherapies may have favorable long-term safety
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profiles [9, 10], though ongoing studies are validating
this in children.
However, brainstem gliomas like DIPG provide unique
challenges for immunotherapy. Physiologically, the brain-
stem controls vital functions [11], requiring that therapies
avoid damage to healthy tissue. Infectious or autoimmune
inflammation of the brainstem carries high morbidity and
mortality [12], raising concerns for cancer immunother-
apies in this location. Additionally, DIPGs contain few
adaptive immune cells, suggesting a lack of functional
immunosurveillance and a need for induction of de novo
immune responses [13, 14].
These data raise the question of whether potentially cura-
tive immunotherapy for brainstem tumors may generate
unacceptable toxicity. Preclinically, cancer vaccines [15]
and CAR T cells [16] have been studied in DIPG xenograft
models, establishing evidence of anti-tumor efficacy. How-
ever, while these human xenograft models allow for proof-
of-concept efficacy, exploration of immune-mediated tox-
icity and associated inflammation is best recapitulated in
an immunocompetent animal model. To this end, we used
previously-validated syngeneic gliomas and melanomas to
establish brainstem tumor models to assess a diverse range
of immunotherapies. Our goal was not to compare relative
efficacies of each therapy, but rather to ascertain the poten-
tial for immune-mediated toxicity in the brainstem. From
these studies, we demonstrate that although the possibility
of therapy-related inflammatory toxicity exists, a diverse
range of immunotherapies can extend survival of mice
bearing syngeneic brainstem tumors without generating
overt neurologic toxicity. These results suggest greater con-
sideration of clinical immunotherapy trials for pediatric
brainstem tumors.
Materials and methods
Cell lines and viruses
GL261 and GL261-QUAD cells were obtained from Dr.
Aaron Johnson (Mayo Clinic). GL261-QUAD cells were
originally created by John Ohlfest, et al [17], and stably
express the model tumor antigens chicken OVA257–264,
chicken OVA323–339, human gp10025–33, and the mouse al-
loantigen I-Ea52–68. Both GL261 tumor lines were grown in
DMEM (HyClone, Logan, UT, USA) + 10% FBS (Life Tech-
nologies, Carlsbad, CA). B16.F1 parental murine melanoma
cells were obtained from the ATCC (Manassas, VA). B16tk
cells were derived from a B16.F1 clone stably infected with
a lentivirus expressing the Herpes Simplex Virus thymidine
kinase (HSV-1 TK) gene. Following stable selection in
1.25 μg/mL puromycin, these cells were shown to be sensi-
tive to Ganciclovir (APP Pharmaceuticals, Barceloneta, PR)
at 5 μg/ml. B16tk cells were grown in DMEM (HyClone,
Logan, UT, USA) + 10% FBS (Life Technologies, Carlsbad,
CA) + 1.25 μg/mL puromycin (Sigma, St. Louis, MO) until
challenge. B16-ova cells were B16.F1 cells transfected with
pcDNA3.1OVA and maintained in 10% DMEM with 5mg/
mLG418 selection media. The B16-EGFRvIII cell line was
generated by retroviral transduction with pBABE PURO
encoding the murine EGFRvIII modified by the deletion of
500 aa from the intracellular domain of the protein using a
construct given as a kind gift from Dr. Luis Sanchez-Perez
and Dr. John Sampson (Duke University, Durham, NC)
[18]. A clonally derived cell line was subsequently main-
tained in 1.25 μg/mL of puromycin.
Cell lines were authenticated by morphology, growth
characteristics, PCR for melanoma specific gene expres-
sion (gp100, TYRP-1 and TYRP-2) and biologic behavior,
tested mycoplasma-free, and frozen. EGFRvIII-positive
cells were verified by flow cytometry staining with an anti-
EGFRvIII primary antibody (L8A4). Cells were cultured
less than 3months after thawing. Cells were tested for
mycoplasma using the MycoAlert Mycoplasma Detection
Kit (Lonza Rockland, Inc. ME, USA).
For recombinant vaccinia virus (VV) production, CV-1
cells were infected by vaccinia virus (WR strain) and trans-
fected with the pSC65 plasmid transfer vector (a generous
gift from Dr. Bernard Moss, NIAID) containing murine
granulocyte monocyte colony stimulating factor (GM-CSF)
cDNA [19]. Recombinant viruses were isolated and then
bulked up in Hela cells (ATCC, Manassass, VA), followed
by sucrose cushion purification. Purified virus was titered
on Hela cells and stored at -80C. Clinical-grade reovirus
was acquired from Oncolytics Biotech (Calgary, Canada).
GL261 cells were infected with reovirus or VV-
GMCSF at an MOI of 10 followed by exposure to Cell
Titer Blue (Promega) for survival assessment or harvest-
ing for replication assessment using a plaque assay on
Hela cells (vaccinia) or L929 cells (reovirus).
All vesicular stomatitis viruses (VSV) were generated
as previously described [20]. Briefly, VSV (Indiana sero-
type) expressing human gp100 or chicken ovalbumin
was generated by cloning the respective antigen into the
pVSV-XN2 plasmid by inserting between the VSV G and
L proteins. VSV was titered by plaque assay on BHK
cells and stored at -80C.
Mice
Female C57BL/6 mice at 6–8 weeks of age (Jackson
Labs) were used for all in vivo experiments. OT-I [21]
and pmel [22] mice were bred at the Mayo Clinic, and
harvested between 8 and 14 weeks of age for adoptive
transfer experiments.
Transgenic T cell preparation
Pmel or OT-I T cells were harvested from transgenic
pmel or OT-I mouse spleens, respectively, and under-
went a magnetic bead negative sort for CD8+ cell isola-
tion (Miltenyi Biotec).
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CAR T cell preparation
EGFRvIII-reactive chimeric antigen receptor construct was
obtained as a kind gift of Dr. Steven Feldman (National
Cancer Institute, Bethesda, MD), and CAR T cells were
produced as previously described [23]. In brief, mouse sple-
nocytes were harvested from C57BL/6 mice and activated
in IL2 (50U/mL) and ConA (2.5 μg/mL) for two days. Cells
were transduced with a retroviral construct expressing an
EGFRvIII-reactive scFv followed by CD3zeta, CD28, and 4-
1BB murine intracellular signaling domains, followed by an
IRES and either a luciferase or GFP tag. CAR T cells were
harvested three days later for experimental use.
In vivo studies
C57BL/6 mice were challenged with brainstem tumors via
stereotactic implantation using established coordinates [24].
Mice were monitored daily for gross neurologic symptoms
including gait abnormalities, hunching, lethargy, seizures,
paralysis, circling, and head tilt. Upon presentation of gross
neurologic symptoms or poor body conditioning, mice
were euthanized in accordance with IACUC standards.
For suicide gene therapy studies, mice bearing B16tk
brainstem tumors were treated on days 4–8 and 11–15
with ganciclovir (GCV) (50mg/kg i.p.) (APP Pharmaceuti-
cals). Dexamethasone co-treatment (1.0mg/kg i.p.) (Frese-
nius Kabi) began on day 4 post-tumor implantation and
continued for the remainder of the experiment. For radi-
ation studies, mice received 10Gy of whole brain irradiation
using a Cesium-137 irradiator on day 4 post tumor im-
plantation, followed by GCV on days 6–10 and 13–17.
For oncolytic virotherapy, GL261 glioma cells were
suspended in VV-GMCSF or reovirus at an MOI of 10
(5 × 105 pfu) immediately prior to implantation. Ten-day
established tumors were treated with reovirus or PBS
stereotactic injection. Mice were also treated with anti-
CTLA4 (100 μg/mouse i.p.) (9D9, BioXCell) and anti-
PD1 (250 μg/mouse i.p.) (RMP1–14, BioXCell) anti-
bodies or an IgG control (350 μg/mouse i.p.) (Jackson
ImmunoResearch) on days 10, 13, and 16.
For adoptive cell transfer, mice bearing B16-ova brain-
stem tumors were treated with pmel T cells on day 6
(1 × 106 cells i.v.), and VSV-hgp100 4–6 h later (5 × 106
pfu i.v.). VSV-hgp100 was readministered on days 6 and
8. This protocol was repeated using GL261-QUAD
gliomas, OT-I T cells, and VSV-ova.
For CAR T cell studies, three days after B16-EGFRvIII
tumor challenge, mice received 5Gy of total body irradi-
ation using a Cesium-137 irradiator. One day later, mice
received EGFRvIII-CAR T cells or untransduced controls
(1 × 107 cells IV). Three hours later, mice were adminis-
tered anti-PD1 antibody (250 μg/mouse i.p.) (RMP1–14,
BioXCell) or an IgG control (250 μg/mouse i.p.) (Jackson
ImmunoResearch). Anti-PD1 treatment was repeated on
days 7 and 10.
In vivo MRI and bioluminescence imaging
T1 and T2 MRI images were acquired using a Bruker
DRX-300 (300MHz 1H) 7-Tesla vertical bore small ani-
mal imaging system (Bruker Biospin) as described [25].
Analyze 11.0 software (Biomedical Imaging Resource,
Mayo Clinic) was used by blinded reviewers for image
analysis. Bioluminescence imaging was performed on
CAR T cell-treated mice using an IVIS Spectrum system
(Xenogen Corp.) [25].
Flow cytometry
Brains for flow cytometry analysis were prepared using
dounce homogenization and a Percoll gradient solution
as previously described [26]. Enriched immune cells
were stained using the following antibodies: CD45 (30-
F11 or A20), Thy1.1 (HIS51), CD4 (GK1.5), CD8 (53–
6.7), GR1 (RB6-8C5), CD11b (M1/70), CD11c (HL3),
NK1.1 (PK136), CD19 (6D5), I-A/I-E (MHCII) (M5/
114.15.2), and fixable live dead viability dye (Zombie
NIR).
VITAL killing assay was performed as previously de-
scribed [27]. Briefly, B16-EGFRvIII targets or parental B16
non-target cells were stained with CellTrace Violet (Mo-
lecular Probes, Eugene, OR) or CellTrace CFSE (Molecu-
lar Probes, Eugene, OR) prior to plating at a 1:1 ratio.
CAR T cells were then co-incubated for 24 h, followed by
fixable live dead staining with Zombie NIR (Biolegend,
San Diego, CA). The target:nontarget ratio at various ef-
fector:target ratios was used to calculate specific killing.
For ex vivo T cell restimulation, spleens from pmel/
VSVhgp100-treated mice were made into a single cell sus-
pension and plated. hgp10025–33 (cognate pmel antigen) or
SIINFEKL (ovalbumin antigen) were added at 5 uM to the
prepared splenocytes and incubated at 37C. Two hours
later, brefeldin A (Cytofix/Cytoperm Plus, BD, Franklin
Lakes, NJ) was added, followed by 4 more hours of incuba-
tion. At that time, flow cytometry surface staining was per-
formed using the following antibodies: anti-Thy1.1 (HIS51),
anti-CD4 (GK1.5), anti-CD8 (53–6.7), and fixable live dead
viability dye (Zombie NIR). Cells were then permeabilized
and intracellularly stained with: anti-IFNg (XMG1.2), anti-
TNFa (MP6-XT22), and anti-IL2 (JE56-5H4).
Histology and immunofluorescence
All tissues were fixed in 10% formalin, sectioned, and em-
bedded in paraffin or underwent H&E staining (Mayo
Clinic Histology Core Facility). Immunofluorescence stain-
ing was performed based upon established protocols [28].
Briefly, slides were deparaffinized in a series of washes of
decreasing ethanol content. CD3, GFP, CD11b-stained
slides underwent heat-mediated antigen retrieval using so-
dium citrate buffer, while VV-stained slides used Tris/
EDTA buffer. Slides were then stained with anti-CD3
(ab16669, Abcam, Cambridge, MA), anti-VV (ab35219,
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Abcam, Cambridge, MA), anti-GFP (ab6556, Abcam, Cam-
bridge, MA), or anti-CD11b (ab133357, Abcam, Cam-
bridge, MA) antibodies, followed by secondary staining
with an AF568-tagged goat anti-rabbit antibody (A11011,
Invitrogen, Carlsbad, CA) and counterstaining with DAPI.
Images were acquired with an LSM780 confocal micro-
scope and Zen software (Carl Zeiss, Thornwood, NY).
Quantification was performed using ImageJ for tumor area
calculation and blinded manual counting of CD3+ cells.
Statistics
Mantel-Cox Log-Rank test with Holm-Bonferroni cor-
rection for multiple comparisons was used to analyze
Kaplan-Meier survival curves. Student’s T tests with
Holm-Bonferroni correction for multiple comparisons
were used for in vitro and ex vivo analysis where ap-
propriate. Statistical significance was set at p < 0.05
for all experiments. All analysis was performed within
GraphPad Prism 6 software.
Results
Suicide gene therapy
We and others have shown that suicide gene therapy
acts through an inflammatory mechanism dependent
upon immune effectors [29, 30]. To model this thera-
peutic strategy, we used published brainstem coordinates
[24] to stereotactically implant B16 murine melanomas
stably expressing herpes simplex virus thymidine kinase
(B16tk), which are sensitive to ganciclovir (GCV) pro-
drug treatment. Although melanomas do not frequently
metastasize to the brainstem, this model was well-
characterized in our laboratory and maintained high ex-
pression of the suicide gene, maximizing the potential
for therapeutic toxicity. Similar to aggressive brainstem
gliomas, untreated mice succumbed to disease within
10–15 days, with tumor location confirmed by MRI and
histology (Fig. 1A). When treated with GCV, mice sur-
vived significantly longer than untreated controls
(Fig. 1B) with decreased tumor growth (Fig. 1C). Im-
portantly, gross neurologic examination during GCV
treatment did not reveal any deficits or other signs of
therapy-related toxicity. To assess compatibility with
clinical treatments, we combined suicide gene therapy
with dexamethasone or radiation, both known immu-
nomodulators [31, 32]. Daily concurrent administration
of dexamethasone did not decrease GCV treatment
efficacy (Fig. 1B). Additionally, pretreatment with 10Gy
of whole brain radiation increased survival beyond
A B
C D
Fig. 1 Suicide gene therapy effectively treats brainstem tumors without overt toxicity. (a) B16tk cells (right) or PBS (left) were stereotactically
implanted into the brainstem of C57BL/6 mice that underwent T2 MRI imaging on Day 9. Inset H&E images at 4x. (b) Kaplan-Meier survival curve
for B16tk tumors treated with two five-day courses of GCV and daily dexamethasone. (n = 10 mice/group) Figure is representative of two
independent experiments. (c) Tumor volume assessment by T1 MRI imaging of treated and untreated mice. (n = 3 mice/group) Paired t-test of
the difference in tumor volumes between Days 5 and 9 for each group. (d) Kaplan-Meier survival curve for B16tk tumors treated with 10Gy whole
brain irradiation and GCV. (n = 9 mice/group) Figure is representative of one experiment
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PBS-treated mice, and radiation enhanced GCV therapy
(Fig. 1D).
Whole brain flow cytometry of GCV-treated mice three
days after treatment initiation demonstrated an increase in
NK cells, antigen presenting cells, and microglia (Fig. 2A,
B), suggesting innate immune activation in response to
suicide gene-induced cell death. Thirteen days later, this
led to an increase in CD4 and CD8+ T cell infiltration in
GCV-treated mice (Fig. 2C). No change was observed six
or thirteen days after treatment in CD45Hi cells, or B cells,
NK cells, dendritic cells, or macrophages within that popu-
lation (not shown). Immunofluorescence staining con-
firmed an increase in CD3+ mononuclear infiltrates
(Fig. 2D,E). These data show that directly-cytotoxic,
inflammatory therapies such as suicide gene therapy can
effectively treat brainstem tumors in the absence of overt
toxicity.
Oncolytic viroimmunotherapy
To test highly inflammatory therapies, we selected two vi-
ruses with differing replication kinetics and immunogenic-
ities. The first was serotype-3 Dearing strain reovirus with
immune-dependent anti-tumor efficacy previously used in
clinical trials to treat glioblastoma [33, 34]. The second virus
was an attenuated, highly-inflammatory vaccinia virus ex-
pressing granulocyte-monocyte colony stimulating factor
(VV-GMCSF), which has been studied previously in gliomas
and generates an innate and adaptive anti-tumor immune
response [35, 36]. Both viruses replicated in GL261 cells in
vitro, although only vaccinia virus killed cells within one
week (Fig. 3A). To model maximal viral replication, killing,
and inflammatory toxicity, GL261 cells were mixed with
each virus immediately prior to implantation into the brain-
stem of C57 mice. Within several days, mice receiving VV-
GMCSF began losing weight and exhibited overt neurologic
symptoms such as hunching, lethargy, and ataxia, with 33%
of mice requiring euthanasia (Fig. 3B). A CD11b +menin-
geal cellular infiltrate was observed in regions also positive
for vaccinia antigen (Fig. 3C). Interestingly, mice surviving
initial VV-GMCSF-related toxicity were tumor-free after
150 days (Fig. 3B). Reovirus-treated mice did not develop
neurologic symptoms requiring euthanasia, but similarly
remained tumor-free for 150 days (Fig. 3B). Because of its
ability to prevent tumor development in the absence of
toxicity, we tested reovirus against established GL261 brain-
stem tumors. Surprisingly, injection of GL261 brainstem
tumors on Day 10 with escalating doses of reovirus neither
improved survival over PBS-injected controls, nor demon-
strated any toxicity (Fig. 3D). In a corollary experiment,
mice were sacrificed seven days after viral administration
for histological examination of CD11b and CD3 expression.
While CD11b + cells were not observed (not shown), CD3+
cells were present in the brainstem of Reovirus-treated mice
(Fig. 3E), suggesting that while T cells were recruited to the
brainstem, their activity may have been inhibited. Based on
previous studies in gliomas [37, 38], we hypothesized that
immunosuppressive factors may be restricting reovirus’ abil-
ity to elicit an anti-tumor immune response. To overcome
this, we tested anti-PD1 and anti-CTLA4 immune check-
point blockade to increase the potential for additive inflam-
matory toxicity or enhanced efficacy. We did not observe
any overt toxicity in mice treated with either ICB alone or
in combination with reovirus. However, while neither ICB
nor reovirus significantly extended survival as monother-
apies, combination therapy led to enhanced survival over
sham-treated controls (p = 0.035 after correction for mul-
tiple comparisons) (Fig. 3F). These data suggest that al-
though there is potential for inflammatory toxicity, direct
administration of certain viruses can treat brainstem tu-
mors, especially in combination with immune checkpoint
blockade.
Adoptive T cell transfer therapy
Next, we tested whether an anti-tumor, T cell-mediated
therapy could be tolerated in the brainstem. We have previ-
ously shown that naïve transgenic T cells transferred into
mice can be activated in vivo by viral expression of their
cognate antigens, leading to regression of flank tumors or
metastases [39–41]. Mice bearing brainstem B16 melano-
mas were treated with naïve pmel transgenic T cells recog-
nizing the murine melanoma antigen gp100, followed by
three doses of VSV expressing human gp100 (VSV-hgp100),
a known heteroclitic activator of pmel T cells [39, 41]. Add-
itionally, these tumors expressed the model antigen ovalbu-
min (ova), for subsequent evaluation of antigen spread in
the endogenous T cell compartment. When treated with
either pmel T cells or VSV-hgp100 alone, mice succumbed
to disease alongside untreated controls (Fig. 4A). However,
treatment with both therapies significantly extended median
survival by 16 days compared to untreated controls. To
establish that this effect was neither antigen nor tumor spe-
cific, we repeated these studies using a GL261-QUAD mur-
ine glioma model [17], OT-I T cells, and VSV expressing
ovalbumin (VSV-ova). Although this tumor’s immunogen-
icity caused it to be spontaneously rejected in half of the
mice, OT-I T cell and VSV-ova treatment did not elicit any
inflammatory toxicity, and treated mice survived signifi-
cantly longer than untreated controls (Fig. 4B).
Whole brain flow cytometry of mice treated with pmel
T cells and VSV-hgp100 showed a significant increase in
pmel (Thy1.1+) T cells three days after the last VSV dose,
and a trend towards significance for endogenous (Thy1.1-)
CD4 and CD8 T cells compared to monotherapy or un-
treated mice (Fig. 5A). To confirm T cell brainstem infil-
tration, immunofluorescence staining demonstrated an
increase in CD3+ mononuclear cells localized to the
tumor in pmel T cell/VSV-hgp100-treated mice (Fig. 5B).
Importantly, splenic pmel T cells from treated mice
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secreted inflammatory cytokines ex vivo in response to
their cognate antigen, though endogenous CD8 T cells
were unresponsive to either the vaccinated antigen
(hgp100) or a tumor antigen (ovalbumin-derived SIIN-
FEKL) (Fig. 5C). Together, these data suggest that T cell
therapy with activated anti-tumor T cells generates brain-
stem infiltrates that exert anti-tumor activity without overt
evidence of toxicity.
Chimeric antigen receptor (CAR) T cell therapy
To model a clinically-relevant T cell immunotherapy, we
used a retroviral, third-generation murine CAR construct
targeting epidermal growth factor receptor variant III
(EGFRvIII), a commonly mutated receptor in glioblastoma
[42]. Although EGFRvIII is not expressed by pediatric
brainstem tumors, it served as a model antigen in this
context. This construct successfully transduced murine
splenocytes to more than 70% CAR positivity (Fig. 6A),
with the resulting CAR T cells successfully and selectively
killing B16 murine melanomas stably expressing EGFRvIII
(B16-EGFRvIII) in the presence of parental B16 cells in
vitro (Fig. 6B). Subsequently, B16-EGFRvIII cells were
implanted into the brainstem, and following 5Gy total
body irradiation (TBI) for partial lymphodepletion
[42], EGFRvIII-CAR, luciferase-tagged T cells were
administered intravenously. Mice receiving TBI and
EGFRvIII-CAR T cells survived significantly longer
than mice receiving untransduced T cells (UTD)
(Fig. 6C). However, anti-PD1 checkpoint blockade did
not significantly impact survival, but also did not
A B
C D
E
Fig. 2 Suicide gene therapy generates brainstem inflammation. (a,b,c) Whole brain flow cytometry of mice bearing B16tk brainstem tumors
treated with GCV or PBS from Days 4–8 and 10–14 post-tumor implantation. Leukocytes were gated as CD45Hi; Microglia were gated as CD45Mid,
CD11b+; APCs were gated as CD45Hi and either CD11b+, CD11c + or MHCII+. * p≤ 0.05 (n = 3–4 mice/group) (d) Representative histology from
(c). H&E (20x, top) and anti-CD3 (red)/DAPI (blue) (40x, bottom), with quantitation in (e). * p < 0.05
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induce toxicity. Using IVIS imaging, CAR T cells were
visualized in the brainstem as early as one day post-
administration (Fig. 6D), which was histologically
confirmed using GFP-tagged CAR T cells (Fig. 6E).
During this therapeutic window where T cells were
present in the brainstem, mice receiving CAR T cells
did not exhibit any neurologic symptoms or weight
loss (Fig. 6F). Our data here suggest that CAR T cell
therapy, which is currently approved for CD19+ liquid
malignancies, may have a favorable safety profile in
brainstem tumors. However, these murine models
provide limited opportunity to evaluate toxicities ex-
perienced in human trials, due to the highly specific
nature of each CAR target.
A B
C
F
D
E
Fig. 3 Immunostimulatory oncolytic virotherapy in the brainstem demonstrates both inflammatory toxicity and anti-tumor efficacy. (a) GL261 cells
were infected in vitro with VV-GMCSF or reovirus (MOI 10). Cell survival (left y-axis, solid bar) or viral titers (right y-axis, dashed bar). (b) Kaplan-
Meier survival curve for mice receiving VV-GMCSF/GL261, Reo/GL261, or PBS/GL261 co-implantation. (n = 9 mice/group) Figure is representative of
two independent experiments. (c) Representative mouse euthanized for neurologic symptoms four days after VV-GMCSF and tumor co-
implantation. H&E image (left, 10x); midbrain (Mid) and medulla (Med), with black arrowhead to indicate inset meningeal infiltrate (vaccinia
antigen, red, 40x, middle; CD11b, red, 40x, right). (d) Kaplan-Meier survival curve for 10-day established GL261 tumors treated intratumorally
with escalating doses of reovirus. (n = 9 mice/group) Figure is representative of three independent experiments. (e) Representative mice
euthanized seven days after reovirus or PBS treatment for histologic analysis. H&E image (left, 20x) and anti-CD3 (red)/DAPI (blue) (right, 40x).
(f) Kaplan-Meier survival curve for 10-day established GL261 tumors treated with reovirus (2.5E6 pfu) or PBS, followed by anti-CTLA4/anti-PD1
therapy. (n = 5–6 mice/group) Figure is representative of two independent experiments
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Discussion
The goal of this study was to investigate whether inflam-
matory, immune-based therapies are likely to be too dan-
gerous for the treatment of pediatric brainstem tumors.
While cancer immunotherapy has shown remarkable
clinical promise, these benefits derive from a highly in-
flammatory mechanism of action involving both innate
and adaptive immune effector cells. Tumors growing in
the brainstem present largely unique clinical challenges in
this respect because of the potential for life-threatening
A B
Fig. 4 Transgenic T cell therapy extends survival in mice bearing syngeneic brainstem tumors. (a) Kaplan-Meier survival curve for B16-ova tumors were
treated with PBS or pmel T cells, followed 4–6 h later by PBS or VSV-hgp100 and two follow-up doses of VSV-hgp100 or PBS. (n= 9 mice/group) Figure is
representative of three independent experiments. (b) Kaplan-Meier survival curve for mice bearing GL261-QUAD tumors treated with PBS or OT-I T cells,
followed 4–6 h later by PBS or VSV-ova and two follow-up doses of VSV-ova or PBS. (n= 18 mice/group) Figure is representative of one experiment
A B
C
Fig. 5 Transgenic T cells traffic to the brainstem and recruit endogenous immune cells. (a) Whole brain flow cytometry of mice treated as
described in Fig. 4A. Analysis performed on Day 15 post-tumor implantation. * p≤ 0.05 (n = 3 mice/group) (b) Representative histology from (a).
H&E (20x, top) and anti-CD3 (red)/ DAPI (blue) (40x, bottom). (c) Splenocytes from mice treated with pmels and VSV-hgp100 and harvested in (a)
and (b) were incubated for 6 h with vehicle, hgp10025–33, or SIINFEKL (ovalbumin immunogenic peptide), and underwent intracellular staining for
cytokines. (n = 3 mice/group)
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inflammation-driven swelling. Hence, whereas pseudopro-
gression is now recognized as a clinically beneficial sign of
immunotherapeutic success [43], the recruitment of such
immune effectors into the space-limited context of a
tumor in the brainstem may be more dangerous than the
tumor itself. Therefore, our goal was to test the hypothesis
that inflammatory therapies would be catastrophically
toxic for the treatment of brainstem tumors.
To this end, we used stereotactic implantation to es-
tablish syngeneic brainstem tumors in immunocompe-
tent mice. The use of fully immunocompetent models
was critical because we wished to investigate the inter-
action of immune-mediated therapies with tumor cells
as well as with endogenous effectors of both the innate
and adaptive immune system. For these studies, we used
tumor lines which we have previously validated as
optimally sensitive to the therapies that we tested –
namely B16tk, GL261, B16-ova, GL261-QUAD, and B16-
EGFRvIII. Although these are not pediatric brain tumor
cells, they represent experimental scenarios where we are
most likely to observe anti-tumor efficacy and therapy-
related toxicity in an immunocompetent system.
A B C
D
F
E
Fig. 6 CAR T cells traffic to the brainstem and extend survival without overt toxicity. (a) EGFRvIII-CAR transduction quantification using
biotinylated protein L and streptavidin-PE staining. (b) VITAL assay of B16-EGFRvIII-specific killing over B16-parental cells by EGFRvIII-CAR T cells
after 24 h. (n = 2) (c) Kaplan-Meier survival curve of B16-EGFRvIII brainstem tumors treated with 5Gy total body irradiation followed by EGFRvIII-
CAR T cells or untransduced controls and anti-PD1 antibody or IgG control. (n = 8 mice/group) Figure is representative of two independent
experiments. (d) Representative IVIS bioluminescent images of EGFRvIII-CAR-Luciferase treated mice. (e) Representative mice bearing B16-EGFRvIII
brainstem tumors sacrificed for histologic analysis four days after GFP-tagged CAR administration. H&E (left, 20x) and anti-GFP (green)/DAPI(blue)
(right, 40x) (f) Serial weight measurements from (c). (n = 8 mice/group)
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Our first model was an optimal scenario for therapy in
which 100% of the tumor cells were engineered to express
the therapeutic HSVtk gene. Ours and others’ previous
studies have shown that HSVtk/GCV tumor killing is
highly inflammatory, generating both innate and adaptive
immune responses [29, 30, 44]. Therefore, this first model
was chosen to test the toxicity of massive tumor cell death
associated with innate immune activation and subsequent
T cell recruitment. Our data clearly show that drug-
induced tumor killing in the brainstem was significantly
more beneficial than toxic (Fig. 1B-D), despite the dramatic
immune infiltration that was observed (Fig. 2). We also
confirmed that current standard of care radiation therapy
or dexamethasone could be effectively combined with this
cytotoxic immunotherapy (Fig. 1B, D). Dexamethasone co-
treatment was also performed with oncolytic virus and T
cell therapies, but had no significant effect on overall sur-
vival or therapeutic toxicity.
Our results here support the development of direct in
vivo delivery of suicide genes such as HSVtk for the treat-
ment of pediatric tumors such as DIPG. One promising
drug delivery technique is convection enhanced delivery
(CED), which was used in two recently completed clinical
trials treating DIPG [45, 46]. While neither trial used
immune-activating therapies, toxicity profiles were gener-
ally tolerable, with most neurologic symptoms resolving
within four weeks after therapy. In light of these promising
results, we are developing rodent models of convection en-
hanced delivery to test viral vectors expressing such genes.
The suicide gene therapy model demonstrated that
inflammation associated with synchronized killing of
tumors in the brainstem is not itself necessarily fatal.
Therefore, we next tested oncolytic virotherapy, which
we hypothesized would be significantly more inflamma-
tory than HSVtk/GCV-mediated cell killing. In this
respect, we have previously shown that oncolytic vir-
otherapy is highly immunostimulatory through associ-
ation with both tumor cell death and the presence of
multiple viral immunogens and TLR activators [47].
Using two different oncolytic viruses, we again tested
the best case scenario in which 100% of tumor cells were
infected with either reovirus or with vaccinia virus (VV-
GMCSF). Unlike treatment with HSVtk, we observed
some acute, fatal toxicity with VV-GMCSF, with histo-
logic analysis confirming the presence of a meningeal
immune infiltrate (Fig. 3B,C). However, those mice
which survived the toxicity were tumor free after 150
days, implying complete tumor clearance by either direct
viral oncolysis, immune-mediated clearance, or both.
Interestingly, mice injected with tumor cells pre-infected
with reovirus did not develop similar catastrophic tox-
icity yet were also tumor free after 150 days. This effica-
cious response to reovirus in the absence of toxicity led
us to perform subsequent studies of direct intratumoral
injection into established tumors. In these studies, reo-
virus was neither more toxic nor therapeutic than con-
trol treatment (Fig. 3D). It remains a formal possibility
that the reovirus did not infect each established GL261
tumor. However, we believe that this is unlikely based
on several lines of evidence. In the first instance, our in
vitro data (Fig. 3A) demonstrate that GL261 cells ex-
posed to reovirus are readily infected and support reo-
virus replication. Second, injection of 2 μl of trypan blue
into the brainstems of mice showed a diffuse and region-
ally comprehensive distribution, suggesting that even if
the injection itself missed the tumor the tumor cells
would be exposed to injected virus. Finally, because of
the potential for variability in the injection procedure,
we used identical stereotactic coordinates and operators
for injection of both tumor cells and subsequent virus in
three independent experiments, all of which showed the
similar result that reovirus alone did not significantly in-
crease survival.
Previous studies using oncolytic viruses to treat glioma
[37, 38] led us to hypothesize that inhibitory receptors
may be blunting the anti-tumor immune response, so
we also added anti-CTLA-4 and anti-PD1 combination
immune checkpoint blockade (ICB). Surprisingly, the
addition of ICB did not cause observable toxicity, but in-
creased survival beyond untreated controls (Fig. 3E). We
have previously shown that systemic delivery of reovirus,
in combination with GMCSF, led to therapy for both
B16 and GL261 tumors in the temporal lobe of the brain
and that addition of anti-PD1 ICB enhanced therapy
[38]. Based on those and our current data, we are cur-
rently investigating the mechanisms by which reovirus
replication, oncolysis, and immune activation are limited
in established brainstem tumors following intratumoral
injection and are testing systemic delivery of reovirus to
the brainstem. In summary, our data show that the use
of different viruses can be tolerated to different extents
and support the cautious investigation of oncolytic vir-
otherapy for brainstem tumors.
Both the suicide gene and oncolytic virus models of im-
munotherapy depend upon recruitment of potent innate
immune responses prior to the development of adaptive T
cell responses. Therefore, we went on to test the balance
between toxicity and efficacy of therapies mediated directly
by T cells. Importantly, our adoptive T cell transfer models
required only systemic administration of T cells with no
need for direct delivery of the therapeutic to the brainstem
tumor itself. In our two different models of adoptive T cell
therapy using transgenic and CAR T cells, we observed sig-
nificant survival extension without overt symptoms of
neurologic or systemic toxicity (Fig. 4-6). We showed that
therapeutic T cells trafficked to the tumor site and that
therapy was dependent solely upon activation of the adop-
tively transferred T cells. Of particular importance, we did
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not observe overt signs of Cytokine Release Syndrome
(CRS) or the related neurotoxicity frequently observed in
clinical trials of CAR T cell therapy( [48, 49])This is in con-
trast to a study of CAR T cells against brainstem xenografts
that demonstrated lethal toxicity in several mice, with fre-
quency increasing in thalamic tumors [50]. This suggests
that while the potential for CAR toxicity in the CNS
exists, it is likely location-dependent and may be
reduced by the presence of an endogenous immune
system. Alternatively, CAR T cell adverse events have
been shown to be related to tumor burden [51, 52],
suggesting that treatment of smaller brainstem tumors
may reduce CRS or neurotoxicity.
While these syngeneic models effectively model the host
response to potentially toxic viro- or immunotherapies,
they have several limitations that will inform future stud-
ies. Unlike the transplantable tumors that we used in our
current studies, DIPG and other high grade gliomas are
highly infiltrative, with tumor cells found in distant, other-
wise normal tissue [53]. While we hypothesize that vir-
oimmunotherapies are potentially capable of controlling
this type of infiltrative disease due to diffusion of virus
and migration of T cells [54, 55], this may also result in
diffuse therapeutic toxicity. Future studies in genetically
engineered mouse models will be important to assess both
efficacy and toxicity in more infiltrative tumors.
Clinically it is important to investigate whether the
therapeutic immune infiltrates that we observed in
our studies here, with treatment starting against rela-
tively small tumors, can also be tolerated in the con-
text of symptomatic tumors. In this respect, we have
found that mice in which GCV treatment was initi-
ated just 2 days before tumors became lethal, still tol-
erated the therapy well and survived to similar time
points as mice receiving much earlier therapy (8 days
prior to tumor lethality).
Overall, these studies provide support for continued
clinical investigation into viro- and immunotherapies for
DIPG, particularly when combined with recent prelimin-
ary results from clinical trials. Treatment of DIPG pa-
tients in Phase I trials using DNX-2401 oncolytic
adenovirus [56, 57], a DIPG lysate-loaded autologous
dendritic cell vaccine [58], and an anti-PD1 antibody
[59] all similarly indicate that the brainstem can tolerate
immunotherapies, though clinical studies to date have
not confirmed immune infiltrates or replicating virus,
nor have they established anti-tumor efficacy. These
clinical results stand in contrast to the pembrolizumab
study for pediatric high grade glioma and DIPG, which
encountered severe adverse events requiring temporary
suspension (NCT02359565). Additionally, patients
receiving CD19-reactive CAR T cells can exhibit neuro-
toxicity, though the mechanism of this event remains
unclear [49]. This suggests that while ours’ and others’
studies suggest a generally favorable toxicity profile,
there are still associated risks that may require detailed
molecular analysis of tumors to predict those that will
respond favorably versus those that will experience ad-
verse events.
Conclusions
In summary, our goal was to investigate whether im-
munotherapy for brainstem tumors was likely to be
too dangerous to pursue. We screened four distinct
models, each shown to be highly efficacious in models
of peripheral tumor immunotherapy and associated
with innate and adaptive components of the immune
system. Of the four models tested, we observed sig-
nificant toxicity only in VV-GMCSF treatment of
murine gliomas in the brainstem. In all four models
we were able to achieve anti-tumor efficacy without
unmanageable toxicity. Our studies here were not de-
signed to compare the relative efficacies of these dif-
ferent immunotherapies or to endorse any specific
modality; such studies will require the development of
efficient in vivo delivery systems, careful testing of
different vectors, transgenes, and T cell targets, and
development of genetically engineered, spontaneous
glioma models to complement the studies described
here. Despite the positive nature of our results show-
ing that immunotherapies can be effective, in the
light of other preclinical and clinical studies discussed
above, we believe that it remains absolutely impera-
tive to regard the brainstem as a site of concern for
immunotherapeutic intervention. Nonetheless, further
careful development of immunotherapies for pediatric
brainstem tumors is warranted to harness the poten-
tial potency of innate and adaptive anti-tumor im-
mune responses, while limiting their possible toxicity
within this anatomically sensitive location.
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